BIO-PATH HOLDINGS Business Summary

Bio-Path Holdings, Inc. (BPTH) is a clinical-stage biotechnology company that operates on a research and development business model, currently generating no revenue from product sales. The company’s value proposition is centered on its proprietary DNAbilize® platform, a unique liposomal delivery technology that enables the systemic administration of neutral-charge antisense RNAi nanoparticle drugs. Its primary business segments are focused on Oncology, with lead candidate prexigebersen (BP1001) in Phase 2 trials for acute myeloid leukemia (AML), and Metabolic Diseases, where it is evaluating BP1001-A for solid tumors and obesity. Bio-Path competes directly with antisense and RNAi therapeutic developers such as Ionis Pharmaceuticals, Alnylam Pharmaceuticals, and Scinai Immunotherapeutics. Within this landscape, Bio-Path occupies a specialized niche as a micro-cap developer of low-toxicity, targeted protein inhibitors designed to overcome the delivery and toxicity hurdles that have historically limited the antisense field. Following a major leadership restructuring in late 2025, the company is currently led by Vikram "Vik" Grover, who serves as President, CEO, and CFO; Grover brings a background as a CFA and attorney with extensive experience in corporate restructuring and capital markets. The company was co-founded by Douglas P. Morris, who remains a central figure as the Chairman of the Board and Director of Investor Relations. Other key members of the leadership team include Anthony Price, Senior Vice President of Finance, and Dr. Ana Ashizawa, Senior Vice President of Research. A notable institutional presence is maintained by Steel Giants Advisors LLC, an entity controlled by CEO Vikram Grover that recently became a majority shareholder and primary financier. In early 2026, the company further strengthened its governance by establishing a Strategic Advisory Board composed of medical research professionals to guide its "BPTH 2.0" strategic pivot and trial restarts.